Altimmune, Inc.ALTNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank23
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P23
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-38.52%
Q3 20259.00%
Q2 2025-5.07%
Q1 202512.27%
Q4 2024-0.40%
Q3 20247.40%
Q2 20240.18%
Q1 202420.31%
Q4 2023-49.17%
Q3 2023-25.17%
Q2 202317.24%
Q1 20235.78%
Q4 20226.70%
Q3 2022-21.36%
Q2 2022-4.60%
Q1 202218.70%
Q4 202127.76%
Q3 2021-33.54%
Q2 2021-67.31%
Q1 2021-38.24%
Q4 202041.34%
Q3 20200.51%
Q2 2020-152.07%
Q1 2020-69.45%
Q4 201961.75%
Q3 2019-217.48%
Q2 2019-52.49%
Q1 201991.48%
Q4 2018-573.87%
Q3 201825.35%
Q2 20189.32%
Q1 201852.29%
Q4 201759.41%
Q3 2017-671.64%
Q2 2017-26.01%
Q1 201742.25%
Q4 2016-38.16%
Q3 2016-685.79%
Q2 201659.52%
Q1 2016-33.38%